Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
U.S. News & World Report10d
Investors Seek Answers on Novo Nordisk's Next-Gen Obesity Drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from ... fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave bed.
Yahoo Finance10d
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO ... Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether it ...
Mint9d
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from ... she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave ...
Yahoo Finance10d
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors ... hammered its shares in December. Novo believes CagriSema could be more powerful than its blockbuster weight-loss ...